semaglutide patient information leaflet Wegovy Pill (oral semaglutide) for weight loss | UK Prescribing Information | Ozempic® (semaglutide)

L.ShihY

At 52 weeks, patients who reached and maintained the target dose of semaglutide (2.4 mg weekly) lost 14.8% of baseline weight

Links to FDA press releases: #FDAGuidance #MASH #DrugDevelopment FDA accepts qualification of non-invasive liver test for MASH As part of the FDAs Drug Development Tool qualification process, the agency has accepted a Letter of Intent for the qualification of Liver Stiffness Measurement by Vibration-Controlled Transient Elastography as a reasonably likely surrogate endpoint for clinical trials in adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced liver fibrosis (scarring)

Gastroparesis Another concern is gastroparesis, which is the delay or stopping of food moving from the stomach and into the intestines